Evidence map›Paper›PMID 37561382›Full record

ReviewCurrent treatment options in oncology2023

Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer.

Fatemeh Davoudi, Afshin Moradi, Therese M Becker, John G Lock, Brian Abbey, Davide Fontanarosa, Annette Haworth, Judith Clements, Rupert C Ecker, Jyotsna Batra

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Association of selectedPathology oncology research : POR · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Fatemeh DavoudiSchool of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, 4059, Australia.
Afshin MoradiSchool of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, 4059, Australia.
Therese M BeckerIngham Institute for Applied Medical Research, University of Western Sydney and University of New South Wales, Liverpool, 2170, Australia.ORCID http://orcid.org/0000-0002-5636-9902
John G LockIngham Institute for Applied Medical Research, University of Western Sydney and University of New South Wales, Liverpool, 2170, Australia.ORCID http://orcid.org/0000-0002-3880-4106
Brian AbbeyDepartment of Mathematical and Physical Sciences, School of Computing Engineering and Mathematical Sciences, La Trobe Institute for Molecular Sciences, La Trobe University, Bundoora, VIC, Australia.ORCID http://orcid.org/0000-0001-6504-0503
Davide FontanarosaSchool of Clinical Sciences, Queensland University of Technology, Gardens Point Campus, 2 George St, Brisbane, QLD, 4000, Australia.
Annette HaworthInstitute of Medical Physics, School of Physics, University of Sydney, Camperdown, NSW, 2006, Australia.ORCID http://orcid.org/0000-0003-1382-7747
Judith ClementsSchool of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, 4059, Australia.ORCID http://orcid.org/0000-0001-6026-1964
Rupert C EckerSchool of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, 4059, Australia.
Jyotsna BatraSchool of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, 4059, Australia. jyotsna.batra@qut.edu.au.ORCID http://orcid.org/0000-0003-4646-6247
Translational Research Institute · AUThe University of Sydney · AUAhvaz Jundishapur University of Medical Sciences · IRLa Trobe University · AUQueensland University of Technology · AUUNSW Sydney · AU

Funding

Advance Queensland 2019001648
6 · The paper itself

Abstract

opinion statementProstate cancer (PCa) is the second most diagnosed malignant neoplasm and is one of the leading causes of cancer-related death in men worldwide. Despite significant advances in screening and treatment of PCa, given the heterogeneity of this disease, optimal personalized therapeutic strategies remain limited. However, emerging predictive and prognostic biomarkers based on individual patient profiles in combination with computer-assisted diagnostics have the potential to guide precision medicine, where patients may benefit from therapeutic approaches optimally suited to their disease. Also, the integration of genotypic and phenotypic diagnostic methods is supporting better informed treatment decisions. Focusing on advanced PCa, this review discusses polygenic risk scores for screening of PCa and common genomic aberrations in androgen receptor (AR), PTEN-PI3K-AKT, and DNA damage response (DDR) pathways, considering clinical implications for diagnosis, prognosis, and treatment prediction. Furthermore, we evaluate liquid biopsy, protein biomarkers such as serum testosterone levels, SLFN11 expression, total alkaline phosphatase (tALP), neutrophil-to-lymphocyte ratio (NLR), tissue biopsy, and advanced imaging tools, summarizing current phenotypic biomarkers and envisaging more effective utilization of diagnostic and prognostic biomarkers in advanced PCa. We conclude that prognostic and treatment predictive biomarker discovery can improve the management of patients, especially in metastatic stages of advanced PCa. This will result in decreased mortality and enhanced quality of life and help design a personalized treatment regimen.

Indexed as

Biomarkers, TumorGenomicsPrecision MedicineProstatic NeoplasmsDisease ManagementHumansMaleNeoplasm StagingPhenotypePrognosisBiomarkers, TumorAdvanced prostate cancerGenotypic biomarkersPhenotypic biomarkersPrecision medicine

Identifiers

PMID37561382
PMCPMC10547634
OpenAlexW4385715354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.